Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer (Q64040346)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Patients With HER2-Positive Breast Cancer |
clinical trial |
Statements
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer (English)
0 references
October 2008
0 references
September 2015
0 references
126
0 references
18 year
0 references
70 year
0 references